Research
Alzheimer's Light and Sound Stimulation Therapy Misses Main Goal in Pivotal Trial
The Brief
- A pivotal trial (HOPE) of an Alzheimer's therapy delivering 40 Hz light and sound stimulation did not meet its primary endpoint.
- The therapy was designed to engage gamma-frequency brain activity.
- The result was reported by MedPage Today from CTAD meeting coverage on 2026-11-20.
Why it matters
A large pivotal trial failing its primary endpoint weakens the case for 40 Hz sensory stimulation as a treatment for Alzheimer's disease, and shapes how researchers and clinicians judge similar non-drug approaches.
Who’s affected
- Alzheimer's researchers and clinicians
- patients and caregivers following non-drug dementia therapies
- #alzheimers
- #clinical trial
- #gamma stimulation
- #neuroscience
- #dementia
(MedPage Today) -- A novel Alzheimer's therapy platform that delivered 40 Hz light and sound stimulation to engage gamma-frequency brain activity did not meet its primary endpoint, the HOPE pivotal study showed. In the primary analysis population...